Ygion Biomedical GmbH has completed a series A financing round of €15 million (US$ 16.3 million) to support the development of individualized neoantigen-based cancer vaccines.
Pheon Therapeutics Ltd. has completed a $120 million series B financing to fund the development of its pipeline of differentiated antibody-drug conjugates (ADCs) for cancer through clinical proof of concept.
May Health SAS closed a $25 million series B financing round to advance its Ovarian Rebalancing therapy for polycystic ovary syndrome (PCOS)-related infertility. The round brings the total funds raised by the Paris-based company to date to $35 million, May Health CEO Anne Morrisey told BioWorld.
A non-traditional route for financing has been the path to success for Fibrobiologics Inc. In the newest BioWorld Insider podcast, CEO Pete O’Heeron offers insight into the company’s unusual path to a Nasdaq listing in January.
RSS
